Last edited 15 Mar 2021

Many small / macro molecule-based STING pathway modulators are currently being evaluated as monotherapies as well as in combination with other drugs, claims Roots Analysis

In recent years, the concept of STING pathway targeting therapeutics has generated a lot of enthusiasm within the medical science community. The growing popularity of this therapeutic technique has not only garnered the interest of several medical researchers (reflected in the increasing volume of scientific literature (1,000+ articles published since 2015) on this subject), but also industry stakeholders focused on drug development (evident in the growing number of clinical trials and the grants awarded for STING focused projects in the recent past).

To order this 310+ page report, which features 170+ figures and 200+ tables, please visit this -

The USD 2.8 billion (by 2030) financial opportunity within the STING pathway targeting technologies market has been analysed across the following segments:

  • Type of STING Modulator
  • Agonist
  • Antagonist
  • Key Therapeutic Area(s)
  • Oncological Disorders
  • Inflammatory Disorders
  • Infectious Diseases
  • Others
  • Route of Administration
  • Intratumoral
  • Intravenous
  • Oral
  • Subcutaneous
  • Others
  • Type of Molecule
  • Non-nucleotide
  • Cyclic Dinucleotide
  • Live Biotherapeutics
  • Oncolytic Peptides
  • Synthetic Peptides
  • Others

The STING Pathway Targeting Therapeutics and Technologies, 2020-2030. report features the following companies, which we identified to be key players in this domain:

  • Aduro Biotech
  • Bristol Myers Squibb
  • Eisai
  • GlaxoSmithKline
  • ImmuneSensor Therapeutics
  • Merck
  • Noxopharm
  • Spring Bank Pharmaceuticals
  • Synlogic

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. STING Pathway Targeting Therapeutics: Current Market Landscape

5. STING Pathway Targeting Technologies: Current Market landscape

6. Company Profiles

7. Academic Grant Analysis

8. STING Related Initiatives of Big Pharmaceutical Players

9. Start-up Health Indexing

10. Publication Analysis

11. Partnerships and Collaborations

12. Funding and Investment Analysis

13. Market Sizing and Opportunity Analysis

14. Executive Insights

15. Concluding Remarks

16. Appendix 1: Tabulated Data

17. Appendix 2: List of Companies and Organizations

To purchase a copy, please visit

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Designing Buildings Anywhere

Get the Firefox add-on to access 20,000 definitions direct from any website

Find out more Accept cookies and
don't show me this again